BUVIDAL®

INTRODUCING THE FIRST WEEKLY/MONTHLY LONG-ACTING INDIVIDUALISED TREATMENT FOR OPIOID DEPENDENCE

BUVIDAL®

INTRODUCING THE FIRST WEEKLY/MONTHLY LONG-ACTING
INDIVIDUALISED TREATMENT FOR OPIOID DEPENDENCE

Buvidal is indicated for:

  • Treatment of opioid dependence within a framework of medical, social and psychological treatment.
  • Treatment is intended for use in adults and adolescents aged 16 years or over.

Administration of Buvidal is restricted to healthcare professionals.

Appropriate precautions, such as to conduct patient follow-up visits with clinical monitoring according to the patient’s needs, should be taken when prescribing and dispensing buprenorphine. Take-home use or self-administration of the product by patients is not allowed.

Buvidal can be administered as either a weekly or a monthly injection.

Buvidal is available in the following doses:

For weekly injection:

Pre-filled syringes containing Buvidal 8 mg, 16 mg, 24 mg and 32 mg prolonged-release solution for injection.

For monthly injection:

Pre-filled syringes containing Buvidal 64 mg, 96 mg and 128 mg prolonged-release solution for injection.

Contact us

Sitemap

Privacy notice

Terms of use

© 2020 Camurus AB. All rights reserved | INT-BUV-1900007 | Date of preparation: February 2019

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close